Controlling secretion to limit chemoresistance

Area of Science:

• Cancer Biology
• Cellular Senescence
• Tumor Microenvironment

Background:

• The tumor microenvironment significantly impacts cancer progression and treatment efficacy.
• Mechanisms underlying these influences, particularly related to therapy-induced cellular changes, remain incompletely understood.

Purpose of the Study:

• To investigate how chemotherapy affects endothelial cells within the tumor microenvironment.
• To elucidate the specific secretory response of chemotherapy-induced senescent endothelial cells.
• To identify signaling pathways regulating these responses and their impact on chemoresistance.

Main Methods:

• Induction of endothelial senescence via chemotherapy.
• Analysis of senescence-associated secretory phenotype (SASP) in endothelial cells.
• Measurement of Interleukin-6 (IL-6) secretion.
• Investigation of the PI3K/AKT/mTOR signaling pathway.

Main Results:

• Chemotherapy triggers endothelial senescence.
• Senescent endothelial cells exhibit an atypical secretory profile, acutely secreting IL-6.
• IL-6 secretion by these cells promotes chemoresistance.
• The PI3K/AKT/mTOR signaling pathway plays a crucial role in restraining the senescence secretory response.

Conclusions:

• Chemotherapy-induced endothelial senescence involves a unique IL-6 secretory response that enhances chemoresistance.
• A physiological switch mediated by PI3K/AKT/mTOR signaling limits detrimental inflammatory consequences of persistent senescence.
• Understanding this mechanism offers insights into modulating tumor microenvironment and improving cancer therapy outcomes.